EA201890148A1 - Способ индукции раннего ответа т-клеток памяти противоопухолевой вакциной из коротких пептидов - Google Patents
Способ индукции раннего ответа т-клеток памяти противоопухолевой вакциной из коротких пептидовInfo
- Publication number
- EA201890148A1 EA201890148A1 EA201890148A EA201890148A EA201890148A1 EA 201890148 A1 EA201890148 A1 EA 201890148A1 EA 201890148 A EA201890148 A EA 201890148A EA 201890148 A EA201890148 A EA 201890148A EA 201890148 A1 EA201890148 A1 EA 201890148A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- inducing
- cells
- memory
- short peptides
- tumor vaccine
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 2
- 230000001939 inductive effect Effects 0.000 title abstract 2
- 230000004044 response Effects 0.000 title abstract 2
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 230000037452 priming Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epoxy Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Настоящее изобретение относится к T-специфической иммунотерапии терапевтическими пептидами для применения в лечении рака у HLA-A2 (человеческий лейкоцитарный антиген A2)-позитивного пациента, где указанное лечение включает период примирования, состоящий из двух-трех применений указанной T-специфической иммунотерапии терапевтическими пептидами, посредством этого индуцируя ответ центральных T-клеток памяти.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2015/064746 WO2017000983A1 (en) | 2015-06-29 | 2015-06-29 | Method for inducing early t memory response with short peptides anti-tumor vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201890148A1 true EA201890148A1 (ru) | 2018-05-31 |
Family
ID=53499000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201890148A EA201890148A1 (ru) | 2015-06-29 | 2015-06-29 | Способ индукции раннего ответа т-клеток памяти противоопухолевой вакциной из коротких пептидов |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11191820B2 (ru) |
| EP (1) | EP3313431B1 (ru) |
| JP (1) | JP6654207B2 (ru) |
| KR (2) | KR20180021882A (ru) |
| AU (1) | AU2015400687B2 (ru) |
| BR (1) | BR112017027653A2 (ru) |
| CA (1) | CA2990299C (ru) |
| DK (1) | DK3313431T3 (ru) |
| EA (1) | EA201890148A1 (ru) |
| IL (1) | IL255722B2 (ru) |
| WO (1) | WO2017000983A1 (ru) |
| ZA (1) | ZA201800434B (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4029494A1 (en) | 2017-01-25 | 2022-07-20 | OSE Immunotherapeutics | Method for manufacturing a stable emulsion for peptide delivery |
| WO2019101347A1 (en) * | 2017-11-27 | 2019-05-31 | Ose Immunotherapeutics | Improved treatment of cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1135181A (zh) | 1993-09-14 | 1996-11-06 | Cytel有限公司 | 使用泛dr结合肽改变免疫应答 |
| AU2004232971A1 (en) * | 2003-04-18 | 2004-11-04 | Idm Pharma Inc. | HLA-A2 tumor associated antigen peptides and compositions |
| EP3320912B1 (en) | 2008-04-17 | 2021-03-31 | IO BIOTECH ApS | Indoleamine 2, 3-dioxygenase based immunotherapy |
| DK2785375T3 (da) | 2011-11-28 | 2020-10-12 | Merck Patent Gmbh | Anti-pd-l1-antistoffer og anvendelser deraf |
| US20140147490A1 (en) | 2012-10-29 | 2014-05-29 | John D. Fikes | Hla class i a2 tumor associated antigen peptides and vaccine compositions |
| KR102043725B1 (ko) * | 2014-11-06 | 2019-11-13 | 오제 이뮈노테라프틱스 | 뇌 전이 치료를 위한 치료용 다중 펩타이드 t 특이적 면역 요법 |
-
2015
- 2015-06-29 BR BR112017027653-4A patent/BR112017027653A2/pt active Search and Examination
- 2015-06-29 AU AU2015400687A patent/AU2015400687B2/en active Active
- 2015-06-29 KR KR1020187002801A patent/KR20180021882A/ko active Application Filing
- 2015-06-29 EA EA201890148A patent/EA201890148A1/ru unknown
- 2015-06-29 CA CA2990299A patent/CA2990299C/en active Active
- 2015-06-29 KR KR1020227002805A patent/KR102571745B1/ko active IP Right Grant
- 2015-06-29 JP JP2017567729A patent/JP6654207B2/ja active Active
- 2015-06-29 DK DK15733431.9T patent/DK3313431T3/da active
- 2015-06-29 EP EP15733431.9A patent/EP3313431B1/en active Active
- 2015-06-29 IL IL255722A patent/IL255722B2/en unknown
- 2015-06-29 WO PCT/EP2015/064746 patent/WO2017000983A1/en active Application Filing
- 2015-06-29 US US15/578,721 patent/US11191820B2/en active Active
-
2018
- 2018-01-22 ZA ZA2018/00434A patent/ZA201800434B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL255722B1 (en) | 2024-01-01 |
| KR102571745B1 (ko) | 2023-08-25 |
| IL255722A (en) | 2018-01-31 |
| AU2015400687B2 (en) | 2021-04-22 |
| DK3313431T3 (da) | 2024-02-12 |
| BR112017027653A2 (pt) | 2018-08-28 |
| NZ737717A (en) | 2021-08-27 |
| CA2990299C (en) | 2023-10-10 |
| CA2990299A1 (en) | 2017-01-05 |
| ZA201800434B (en) | 2018-12-19 |
| KR20220018078A (ko) | 2022-02-14 |
| AU2015400687A1 (en) | 2017-12-14 |
| US20180169200A1 (en) | 2018-06-21 |
| IL255722B2 (en) | 2024-05-01 |
| EP3313431A1 (en) | 2018-05-02 |
| US11191820B2 (en) | 2021-12-07 |
| EP3313431B1 (en) | 2023-11-15 |
| JP2018525343A (ja) | 2018-09-06 |
| JP6654207B2 (ja) | 2020-02-26 |
| KR20180021882A (ko) | 2018-03-05 |
| WO2017000983A1 (en) | 2017-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125260T1 (el) | Παραγοντες δεσμευσης tigit και χρησεις τους | |
| CY1120862T1 (el) | Παραγοντες επαγωγης αποπτωσης για τη θεραπευτικη αγωγη καρκινου και ανοσων και αυτοανοσων ασθενειων | |
| JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
| MX2022003698A (es) | Composiciones de nanoparticulas y metodos para inmunoterapia. | |
| MX2017006408A (es) | Linfocitos t gamma delta modificados geneticamente. | |
| MX2021013837A (es) | Enfoque de inmunoterapias de combinacion para el tratamiento del cancer. | |
| MX2022004374A (es) | Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cancer. | |
| MX2021000083A (es) | Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes. | |
| EA202090751A3 (ru) | Новый метод иммунотерапии нескольких видов опухолевых заболеваний крови, таких как острый миелоидный лейкоз (омл) | |
| CL2017001110A1 (es) | Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva | |
| EA201791150A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака | |
| EA201792642A1 (ru) | Способы диагностики для т-клеточной терапии | |
| MX2019011148A (es) | Metodos de tratamiento. | |
| MX2018001755A (es) | Vacuna contra viruela para tratamiento del cancer. | |
| EA201791736A1 (ru) | Комбинированная терапия для лечения рака | |
| MX2015017959A (es) | Composiciones y metodos para inmunoterapia. | |
| NZ730708A (en) | Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof | |
| EA201792560A1 (ru) | Наночастицы для применения в качестве терапевтической вакцины | |
| MX2017016346A (es) | Metodos de tratamiento con taselisib. | |
| WO2018013855A3 (en) | Il-15/il-15 receptor alpha treatment regimens and use with therapeutic vaccines | |
| EA201890148A1 (ru) | Способ индукции раннего ответа т-клеток памяти противоопухолевой вакциной из коротких пептидов | |
| MX2017005807A (es) | Inmunoterapia especifica de multipeptidos t terapeuticos para el tratamiento de metastasis cerebrales. | |
| MX2018007408A (es) | Uso de adyuvantes para la prevencion y/o el tratamiento de enfermedades autoinmunes. | |
| CY1122083T1 (el) | Καινοτομος ανοσοθεραπεια εναντι ορισμενων ογκων του αιματος, οπως της οξειας μυελογεους λευχαιμιας (ομλ) | |
| MX2019014090A (es) | Métodos para el tratamiento de la reservoritis crónica. |